Elective Bladder-Sparing Treatment for Muscle Invasive Bladder Cancer

被引:2
|
作者
Lendinez-Cano, G. [1 ]
Rico-Lopez, J. [1 ]
Moreno, S. [1 ]
Fernandez Parra, E. [2 ]
Gonzalez-Almeida, C. [3 ]
Camacho Martinez, E. [1 ]
机构
[1] Hosp Univ Nuestra Senora Valme, Serv Urol, Seville, Spain
[2] Hosp Univ Nuestra Senora Valme, Serv Oncol, Seville, Spain
[3] Hosp Univ Nuestra Senora Valme, Unidad Estadist Metodol & Evaluac Invest, Seville, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2014年 / 38卷 / 01期
关键词
Bladder-sparing; Bladder cancer; Radiotherapy; Chemotherapy; Transurethral; resection; BACILLUS-CALMETTE-GUERIN; TERM-FOLLOW-UP; TRANSURETHRAL RESECTION; SELECTIVE BLADDER; INFILTRATING CARCINOMA; RADICAL CYSTECTOMY; PRIMARY CISPLATIN; PRESERVATION; THERAPY; CHEMOTHERAPY;
D O I
10.1016/j.acuro.2013.03.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objetives: Radical cystectomy is the standard treatment for localised muscle invasive bladder cancer (MIBC). We offer a bladder-sparing treatment with TURB +/- Chemotherapy + Radiotherapy to selected patients as an alternative. Material and methods: We analyze, retrospectively, 30 patients diagnosed with MIBC from March 1991 to October 2010. The mean age was 62.7 years (51-74). All patients were candidates for a curative treatment, and underwent strict selection criteria: T2 stage, primary tumor, solitary lesion smaller than 5 cm with a macroscopic disease-free status after TURB, negative random biopsy without hydronephrosis. Staging CT evaluation was normal. Restaging TURB or tumor bed biopsy showed a disease-free status or microscopic muscle invasion. 14 patients underwent TURB alone, 13 TURB + Chemotherapy and 3 TURB + Chemotherapy + Radiotherapy. Results: The mean follow up was 88.7 months (19-220). 14 patients remained disease free (46.6%), 10 had recurrent non-muscle invasive bladder cancer (33%). 81.3% complete clinical response. 71% bladder preserved at 5-years. Overall, 5-years survival rate was 79% and 85% cancer-specific survival rate. Conclusions: Although radical cystectomy is the standard treatment for localised MIBC, in strictly selected cases, bladder-sparing treatment offers an alternative with good long term results. (C) 2013 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:7 / 13
页数:7
相关论文
共 50 条
  • [11] Bladder-sparing therapy for muscle-infiltrating bladder cancer
    Pansadoro, Vito
    Emiliozzi, Paolo
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2008, 5 (07): : 368 - 375
  • [12] Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future
    Koga, Fumitaka
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (11) : 1127 - 1139
  • [13] Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors
    Xu, Chao
    Zou, Wen
    Wang, Yinhuai
    Liu, Xianling
    Wang, Jingjing
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 191
  • [14] Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in Muscle-Invasive Bladder Cancer
    Kumar, A.
    Cherry, D. R.
    Deka, R.
    Nalawade, V.
    Efstathiou, J. A.
    Stewart, T. F.
    Rose, B. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E873 - E874
  • [15] Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer
    Efstathiou, Jason A.
    Choudhury, Ananya
    Kiltie, Anne E.
    [J]. JAMA SURGERY, 2019, 154 (02) : 184 - 185
  • [16] Outcomes of Tri-Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer
    Nguyen, E. K.
    Pond, G.
    Lukka, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E89 - E89
  • [17] Updated results of bladder-sparing trimodality approach for invasive bladder cancer
    Zapatero, Almudena
    Martin de Vidales, Carmen
    Arellano, Ramon
    Bocardo, Gloria
    Perez, Mar
    Rios, Patricia
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (04) : 368 - 374
  • [18] Bladder-sparing radiotherapy for muscle-invasive bladder cancer: A survey of providers to determine barriers and enablers
    Walker, Melanie
    French, Simon D.
    Doiron, R. Christopher
    Brennan, Kelly
    Feldman-Stewart, Deb
    Siemens, D. Robert
    Mackillop, William J.
    Booth, Christopher M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 125 (02) : 351 - 356
  • [19] Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer
    Jiang, Di
    Jiang, Haiyan
    Chung, Peter W. M.
    Zlotta, Alexandre R.
    Fleshner, Neil Eric
    Bristow, Robert G.
    Berlin, Alejandro
    Kulkarni, Girish S.
    Alimohamed, Nimira S.
    Lo, Gregory
    Sridhar, Srikala S.
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : 38 - 45
  • [20] Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives
    Fan, Xinxiang
    He, Wang
    Huang, Jian
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2023, 12 (05) : 802 - 808